Research map: Arsenic trioxide promotes a glue‑like interaction to drive STUB1-mediated NPM-ALK degradation in ALK+ ALCL

Back to the article

Papers in this map

  1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms · Rita Alaggio · 2022 · 4022 citations · Cited by this paper
  2. Cystathionine beta-synthase promotes anoikis resistance and transcoelomic metastasis in ovarian cancer via SP1- ITGB1 regulation · 2026 · Related
  3. Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML · Xiaowei Zhang · 2010 · 788 citations · Cited by this paper
  4. Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications · 2026 · Related
  5. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells · Maria Paola Martelli · 2015 · 154 citations · Cited by this paper
  6. Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML · 2026 · Related
  7. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target · Michael T. Werner · 2016 · 94 citations · Cited by this paper
  8. Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma · 2026 · Related
  9. ALK in cancer: from function to therapeutic targeting · Claudia Voena · 2025 · 37 citations · Cited by this paper
  10. Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting · 2026 · Related
  11. Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma · Wenhua Piao · 2016 · 18 citations · Cited by this paper
  12. Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma · 2026 · Related
  13. A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2 · Yankai Chu · 2025 · 16 citations · Cited by this paper
  14. Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types · 2026 · Related
  15. Characteristics and clinical outcomes of patients with ALK‐positive anaplastic large cell lymphoma: Report from the prospective international T‐cell lymphoma project · CARLOS SÉRGIO CHIATTONE · 2022 · 11 citations · Cited by this paper
  16. Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therapy · 2026 · Related
  17. STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma · Nicole Prutsch · 2024 · 10 citations · Cited by this paper
  18. Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer · 2026 · Related
  19. Lanatoside C activates the E3 ligase STUB1 to inhibit FOXP3 transcriptional activity and promote antitumor immunity · Qian Zhou · 2025 · 9 citations · Cited by this paper
  20. Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy · 2026 · Related
  21. NPM-ALK Oncoprotein Suppresses Anti-Tumor Immune Responses Partially through Cgas-Sting Pathway in ALK+ Anaplastic Large Cell Lymphoma · Ioanna Xagoraris · 2024 · 2 citations · Cited by this paper
  22. Outcomes of Patients with ALK+ Anaplastic Large Cell Lymphoma Refractory or Relapsed after Frontline Chemotherapy · McKenzie Sorrell · 2024 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)